Title
Category
Credits
Event date
Cost
What’s New in Glaucoma Management?
  • Disease management
  • Vision
  • 1.00 AMA - Physicians
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
This activity will explore updated approaches to the management of glaucoma—the “silent thief of sight” that affects an estimated 3 million Americans. It will examine the latest evidence from recent studies on minimally invasive glaucoma surgery (MIGS) procedures and discuss comparative data on more invasive surgical techniques such as trabeculectomy and tube shunt surgery. Patient cases will be introduced to enhance participants’ understanding of the glaucoma treatment process. In addition, potential future innovations in glaucoma treatment will be discussed.
The Diagnostic Odyssey for Individuals With Rare Diseases: Kaposiform Lymphangiomatosis and Other Lymphatic Conditions
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of KLA and other lymphatic conditions, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s).
Sensor-Based Electronic Monitoring for Asthma: A Randomized Controlled Trial
  • Disease management
  • Pediatrics
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide learners with an overview of the prevalence and geographic variability of pediatric asthma, in part through an analysis of data from Chicago, where this variability is especially notable. It will discuss ways to improve pediatric asthma, provide learners with updated management strategies and describe the potential of new technologies, such as sensor-based inhaler monitoring in children, to improve outcomes across diverse populations through an examination of the recent clinical trial, Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC).
Cystic Fibrosis: Utilizing Personalized Treatments and Addressing Health Disparities
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
During this activity, presenters will discuss CF and the different genetic etiologies and examine how an individual’s genetic profile can be utilized to develop a personalized treatment plan. The role that an informed interprofessional health care team can play in improved disease outcomes will also be examined. 
Threading the Needle: Practical Considerations in the Modern, Evidence-based Management of Type 2 Diabetes
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will assist learners in identifying optimal lifestyle and behavioral changes that can impact disease development and progression in their patients and will discuss practical strategies and forms of support that HCPs can offer to assist patients in setting healthy lifestyle goals. Learners will examine how appropriate prescribing decisions must be based on a comparative analysis of diabetes medications and will also review disease etiology and biological changes seen during disease progression. Lastly, the presenter will discuss policy and system changes that can best assist in integrating evidence into daily practice for the purpose of maximizing health in individuals with T2D. 
CMS HEDIS and Stars Pharmacy Overview—Medication Adherence, Statin Use in Patients and More
  • Disease management
  • 2.00 ACPE - Pharmacists
  • 2.00 ACPE - Pharmacy Technicians
  • 2.00 AMA - Physicians
  • 2.00 ANCC - Nurses
  • 2.00 APA - Psychologists
  • 2.00 Attendance - General Attendance
  • 2.00 ASWB - Social Workers
$0.00
Participants in this activity will learn how CMS measures medication adherence, its role in patient qualification status, impact on claims algorithms, and potential caveats of these determinations. Strategies to address common barriers to medication adherence will be discussed, along with best practices that may improve adherence. In addition, the five measures included in the 2021 Medicare Part D star ratings, including those regarding medication adherence for diabetes, hypertension, cholesterol, as well as statin use in persons with diabetes, will be reviewed.
Driving Health Equity Through Technology & Service Innovation
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore how existing health care technology innovations can improve health equity for underserved patients and will examine the changing landscape of provider coverage and reimbursement. It will discuss anticipated solutions for vulnerable individuals (including Medicare and Medicaid dual-eligible individuals) and examine why certain telehealth programs have failed in the past. New approaches to benefit coverage for telehealth-related expenses will also be discussed, along with the future trends and essential elements associated with shifting to quality value-based care that can lead to improved patient satisfaction and outcomes, reduced health care costs and increased levels of health equity.
Preventing Falls in Older Adults: Risk Factors and Interventions
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss The Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) trial, which aims to evaluate the effectiveness of evidence-based strategies to reduce serious fall-related injuries,. In addition, faculty will identify risk factors that contribute to falls in the older adult as well as for individuals in SNFs, and provide interventions to reduce the risk of falls. The importance of a multidisciplinary approach in fall management will also be explored.
Complex Medical Conditions in Children: Utilizing Personalized Treatments and Addressing Health Disparities
  • Disease management
  • Health equity
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will focus on the connection between SDoH and how they may impact access to care, treatment and health outcomes for children with rare and CMC. Learners will be provided with strategies and resources that can address these negative effects. The importance of access to personalized care that they require to live their healthiest lives will be addressed.
Sickle Cell Disease: Understanding Gene Therapy and Addressing Health Disparities
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss the effects and complications of SCD, the prevalence of SCD in different racial and ethnic groups and the role of gene therapy as treatment. Health disparities and challenges in accessing specialized care will also be addressed.

Pages